SIBN

SI-BONE, Inc.

SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.

SI-BONE, Inc. (SIBN) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B- (3.0) C (2.4) B+ (3.7) A- (3.9) C+ (2.6) B- (3.1)
2026-11-07 B- (3.0) C (2.3) B+ (3.7) A- (4.1) C+ (2.7) B- (3.1)
2026-10-31 B- (3.0) C (2.4) B+ (3.6) B+ (3.7) C+ (2.7) B- (3.1)
2026-10-24 B- (3.0) C (2.4) B+ (3.6) B+ (3.6) C+ (2.6) B- (3.1)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe